STEMI Performance in Asia: Current State and Strategies for Improvement
Asia demonstrates substantial heterogeneity in STEMI care delivery, with reperfusion rates ranging from 54% to 92% across countries, median door-to-balloon times of 132 minutes in Beijing and up to 20.9 hours in India, and 2-year mortality between 2.5% and 7.4%—all falling short of guideline-recommended targets that mandate ≤90-minute door-to-balloon times for direct presentations and ≤120-minute first-medical-contact-to-device times for transfers. 1, 2
Current Performance Metrics Across Asia
Reperfusion Rates and Modalities
Overall reperfusion therapy utilization varies dramatically: Korea achieves 91.6% primary PCI rates, while Malaysia relies predominantly on fibrinolysis (72.6%) with only 9.6% receiving primary PCI, and India delivers reperfusion to just 53.9% of STEMI patients. 1
China demonstrates intermediate performance: In Beijing, 80.9% of patients receive reperfusion therapy (65.5% primary PCI, 15.4% fibrinolysis), but in rural Henan province only 35.1% receive early reperfusion. 3, 4
Southeast Asia shows mixed patterns: Primary PCI rates range from 24.8% in India to 65.6% in Northern Europe comparator regions, with fibrinolysis use between 8.1% in China and 34.2% in Southeast Asia. 2
Time-to-Treatment Performance
Door-to-balloon times consistently exceed guideline targets: Beijing reports a median of 132 minutes, with only 22% of patients achieving the ≤90-minute goal recommended by ACC/AHA guidelines. 3, 5
Door-to-needle times for fibrinolysis are also delayed: Beijing's median of 83 minutes means only 7% meet the ≤30-minute guideline target, while rural China achieves 18 minutes but still falls short of optimal performance. 3, 4, 5
First-medical-contact delays are substantial: Median symptom-onset-to-first-medical-contact time in rural China is 168 minutes (2.8 hours), and India reports median time-to-primary-PCI of 20.9 hours—both far exceeding the 120-minute threshold where fibrinolysis becomes preferable. 4, 2, 5
Mortality Outcomes
Two-year mortality demonstrates significant regional variation: Korea/Hong Kong/Singapore achieve 2.5%, China 4.8%, Southeast Asia 5.9%, and India 7.4%—all higher than the 6.2% seen in Japan and substantially above the 9.5% in-hospital mortality achieved by the Vienna STEMI Registry after implementing guideline-based networks. 1, 2, 6
In-hospital mortality in China ranges from 5.4% to 5.8%, comparable to developed regions but reflecting the fact that two-thirds of patients in rural areas receive no reperfusion therapy at all. 3, 4
Guideline-Recommended Targets for Optimal STEMI Care
Time-Based Performance Standards
First-medical-contact-to-device time ≤90 minutes for patients transported directly to PCI-capable hospitals by emergency medical services. 5, 7, 5
First-medical-contact-to-device time ≤120 minutes for patients initially presenting to non-PCI-capable hospitals who require transfer. 5, 7, 5
Door-to-needle time ≤30 minutes when fibrinolytic therapy is the chosen reperfusion strategy at non-PCI-capable facilities. 5, 7, 5
Door-in-door-out time ≤30 minutes for patients arriving at non-PCI hospitals who require immediate transfer for primary PCI. 8, 9
ECG acquisition and interpretation within 10 minutes of first medical contact to establish "time zero" for all subsequent decisions. 8, 10
Reperfusion Strategy Selection Algorithm
Primary PCI is the preferred method when FMC-to-device time can be ≤120 minutes, performed by experienced operators (≥75 PCI cases/year) in high-volume centers (≥36 primary PCI cases/year). 6, 5
Fibrinolytic therapy should be administered within 10–30 minutes of diagnosis when anticipated FMC-to-device time exceeds 120 minutes due to unavoidable delays. 5, 11
Symptom onset ≤3 hours: Primary PCI and fibrinolysis demonstrate comparable mortality if fibrinolysis is delivered within 2–3 hours; the Vienna Registry showed equivalent outcomes when either strategy was initiated within this window. 6, 9
Symptom onset 3–12 hours: Primary PCI is superior to fibrinolysis for mortality and reinfarction reduction; PCI should be pursued regardless of anticipated delays in this time frame. 6, 10
Absolute indications for immediate primary PCI (any time): Cardiogenic shock, acute severe heart failure, contraindications to fibrinolysis, failed fibrinolysis (≤50% ST-segment resolution at 60–90 minutes), and resuscitated cardiac arrest with ST-elevation. 5, 9, 10
Recommended Strategies to Achieve Guideline Targets in Asia
Regional STEMI Network Development
Establish integrated regional systems that coordinate pre-hospital emergency medical services, non-PCI hospitals, and 24/7 PCI-capable centers through standardized written protocols—the Vienna STEMI Registry demonstrated that such networks increased reperfusion rates from 66% to 86.6% and reduced in-hospital mortality from 16% to 9.5%. 6, 9
Implement pre-hospital 12-lead ECG programs with immediate catheterization laboratory activation by EMS personnel before hospital arrival; this intervention is associated with shorter reperfusion times and lower mortality rates. 5
Create direct catheterization laboratory access pathways that bypass emergency departments and intensive care units; the ESC guidelines document a 20-minute time savings with this approach. 8, 10
Designate a central medical director with authority to modify protocols based on continuous performance data and conduct quarterly multidisciplinary meetings to review outcomes. 9
Addressing Geographic and Resource Constraints
Deploy pre-hospital fibrinolysis capability in regions where FMC-to-device times consistently exceed 120 minutes; a 2025 consensus statement for low- and middle-income countries emphasizes this pharmaco-invasive strategy as essential when primary PCI infrastructure is limited. 12
Establish formal transfer agreements between non-PCI and PCI-capable hospitals with pre-specified protocols for immediate patient handoff; door-in-door-out times ≤30 minutes are achievable with such systems. 8, 9
Avoid the "PCI at any cost" pitfall: The Vienna Registry and ACC/AHA guidelines emphasize that fibrinolysis administered within 3 hours of symptom onset is equivalent to delayed PCI, and overreliance on primary PCI when delays are unavoidable leads to worse outcomes than immediate fibrinolysis. 6, 5, 9
Implement a flexible three-model pathway (fibrinolysis model, pharmaco-invasive model, primary PCI model) tailored to local circumstances, as proposed by the STEMI India and Stent Save a Life initiatives. 12
Quality Monitoring and Continuous Improvement
Mandate real-time tracking of all time intervals from symptom onset through reperfusion, with monthly benchmarking reports to all network participants against national standards. 9
Collect and publicly report standardized quality metrics: door-to-ECG, door-to-balloon, FMC-to-device, door-to-needle, and door-in-door-out times, along with 30-day and 1-year mortality stratified by reperfusion strategy. 9
Conduct root-cause analysis of any case exceeding time targets and perform annual reviews of mortality, reinfarction, and bleeding outcomes. 9
Participate in national quality programs such as Mission: Lifeline and the D2B Alliance to access benchmarking data and best-practice resources. 5, 9
Pharmacotherapy Optimization
Ensure universal aspirin administration (150–325 mg orally or 250–500 mg IV) immediately at first medical contact; Asian registries show 97.8% compliance in Beijing but lower rates in rural areas. 3, 10
Administer potent P2Y12 inhibitors (prasugrel or ticagrelor) before or at the time of PCI; clopidogrel use remains high in Asia (89.7% in Beijing) but should be replaced with more effective agents when available. 3, 10
Prescribe evidence-based secondary prevention: Beta-blockers (76.7% in Beijing), ACE inhibitors (73.5%), and statins (91.0%) are underutilized in some Asian regions and require systematic implementation. 3, 10
Critical Gaps Requiring Urgent Attention
Two-thirds of rural Chinese STEMI patients receive no reperfusion therapy, and tertiary hospitals in these regions fail to leverage around-the-clock primary PCI capabilities—referral systems and patient/physician education about reperfusion safety are essential. 4
Median time-to-primary-PCI of 20.9 hours in India indicates catastrophic system failures; immediate implementation of pre-hospital fibrinolysis and pharmaco-invasive strategies is mandatory in such settings. 2
Regional mortality variations persist after adjustment for reperfusion therapy and known prognostic factors, suggesting that unmeasured quality-of-care differences (operator experience, hospital volume, post-procedural management) require targeted investigation and intervention. 2